Here are the stocks added to the Zacks #1 Rank ("strong buy") List today:

Activision Blizzard Inc (ATVI) Aeropostale Inc (ARO) Alexion Pharmaceuticals Inc (ALXN) Basilea Pharmaceutic (BPMUF) BCE Inc (BCE) China Pharma Holdings Inc (CPHI) Comscore Inc (SCOR) DRDGold Ltd (DROOY) EnteroMedics Inc (ETRM) Fidelity National Information Services (FIS) Grand Canyon Education Inc (LOPE) Green Mountain Coffee Roasters Inc (GMCR) Haemonetics Corp (HAE) Hana Biosciences Inc (HNAB) Healthcare Services Group Inc (HCSG) Hecla Mining Co (HL) Merck & Co Inc (MRK) Omnova Solutions Inc (OMN) OSI Systems Inc (OSIS) Radio One Inc (ROIAK) Randgold Resources Ltd (GOLD) Ross Stores Inc (ROST) SupportSoft Inc (SPRT) Tecumseh Products Co (TECUA) Tier Technologies Inc (TIER) Tortoise Capital Resources Corp (TTO) Vertex Pharmaceuticals Inc (VRTX) ...

Here are the stocks added to the Zacks #1 Rank ("strong buy") List today:

Alexza Pharmaceuticals Inc (ALXA) Anesiva Inc (ANSV) Barloworld Ltd (BRRAY) Bio-Reference Laboratories Inc (BRLI) Carmike Cinemas Inc (CKEC) Convergys Corp (CVG) Corus Entertainment Inc (CJR) Gander Mountain Co (GMTN) Hana Biosciences Inc (HNAB) Hellenic Telecom Organization SA (OTE) IntelGenx Technologies Corp (IGXT) Luby's Inc (LUB) NMT Medical Inc (NMTI) Prudential Public Limited Co (PUK) Skyworks Solutions Inc (SWKS) Techne Corp (TECH) Tecumseh Products Co (TECUA) Unilever Plc (UL) View the entire Zacks #1 Rank List.

Zacks Investment Research

Hana Biosciences Inc. (HNAB) has a relatively diversified portfolio but all candidates are in either early stage or middle stage of development. We don’t see huge upside potential for Hana shares in the next 6 to 12 months.

The company’s cash position is also a matter of concern. As of June 30, Hana had aggregate cash and cash equivalents and available-for-sale securities of $9.3 million. When the company advances its candidates into late stage clinical trials, research and development costs will soar in the next few years. Hana may need to tap the capital market as early as in early 2009. Equity financing will dilute shareholder base and reduce its share value.

Hana Biosciences is still a middle-stage development company. Although we are optimistic about its diversified portfolio, we are very concerned about the competition the company will face in the cancer and cancer supportive care areas if its drug

...